2022
Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis
Chow R, Novosel M, So OW, Bellampalli S, Xiang J, Boldt G, Winquist E, Lock M, Lustberg M, Prsic E. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis. BMJ Supportive & Palliative Care 2022, 13: 27-34. PMID: 36194493, DOI: 10.1136/spcare-2022-003815.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyTreatment of CIPNDuloxetine usePeripheral neuropathyRisk ratioPrevention of CIPNSystematic reviewUse of duloxetineSummary risk ratiosClinical practice recommendationsHigh-quality trialsDerSimonian-Laird modelComprehensive systematic reviewCochrane CENTRALSafety profileDatabase inceptionHuman trialsDuloxetinePractice recommendationsLimited evidencePreventionTrialsNeuropathyTreatmentReview
2021
Cancer-related fatigue—pharmacological interventions: systematic review and network meta-analysis
Chow R, Bruera E, Sanatani M, Chiu L, Prsic E, Boldt G, Lock M. Cancer-related fatigue—pharmacological interventions: systematic review and network meta-analysis. BMJ Supportive & Palliative Care 2021, 13: 274-280. PMID: 34593386, DOI: 10.1136/bmjspcare-2021-003244.Peer-Reviewed Original ResearchConceptsCancer-related fatiguePharmacologic interventionsSystematic reviewCochrane Central RegisterFuture clinical trialsMore safety dataCentral RegisterHead trialsControlled TrialsCommon symptomsFuture trialsClinical trialsSafety dataDirect headMean differenceParoxetineModafinilTrialsInterventionPatientsCancer researchReviewPlaceboEMBASEMEDLINE